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SUMMARY 
	
ACOX2 encodes branched-chain acyl-CoA oxidase, a peroxisomal enzyme believed to 
be involved in metabolism of branched-chain fatty acids and bile acid intermediates. 
Deficiency of this enzyme has not been described. We report an 8-year-old male with 
intermittently elevated transaminases, liver fibrosis, mild ataxia and cognitive 
impairment. Exome sequencing revealed a previously unidentified homozygous 
premature termination mutation (p.Y69*) in ACOX2. Immunohistochemistry confirmed 
the absence of ACOX2 expression in the patient’s liver, and biochemical analysis 
showed marked elevation of intermediate bile acids upstream of ACOX2. These findings 
define a novel, potentially treatable, inborn error of bile acid biosynthesis caused by 
ACOX2 deficiency. 
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SIGNIFICANCE STATEMENT 
	
Liver disease of unknown cause represents an unmet medical need. Using exome 
sequencing, we have described a new syndrome associated with homozygous loss of 
ACOX2 featuring elevated transaminases, liver fibrosis, ataxia and cognitive 
impairment. ACOX2 encodes the peroxisomal branched-chain acyl-CoA oxidase and is 
involved in the bile acid biosynthetic pathway. Importantly, this disorder is potentially 
reversible, because the bile acid synthetic pathway can be suppressed with exogenous 
bile acids, diminishing the production of the likely toxic metabolites causing liver and 
neurologic dysfunction. Furthermore, this study provides the means to diagnose ACOX2 
deficiency among other patients with chronic idiopathic liver disease and/or cryptogenic 
cirrhosis. 
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INTRODUCTION 
Despite major advances in Mendelian genetics, the role in normal human biology and 
the impact of mutation of > 75% of the 20,000 protein-coding genes in the human 
	
genome remain to be determined(1). One example of unmet medical need is idiopathic 
liver disease, which remains a challenge in both pediatric and adult hepatology. We and 
others have shown the utility of whole-exome sequencing in the diagnosis of such 
patients (2-6). Children with unexplained liver disease who are the offspring of 
consanguineous union are excellent candidates for having recessive disease-causing 
mutations. Such homozygous mutations can now be readily identified by exome 
sequencing(7). Acyl CoA Oxidase 2 (ACOX2) encodes the branched-chain acyl-CoA 
oxidase believed to participate in the metabolism of branched-chain fatty acids and bile 
acid intermediates in the peroxisomes. While genetic disorders resulting from mutations 
in many other genes in this pathway have been described, mutations in ACOX2 have 
not previously been attributed to a phenotype in humans or other animals. We describe 
a previously unrecognized syndrome resulting from recessive ACOX2 deficiency. 
	
	
	
RESULTS 
	
	
	
	
CASE REPORT 
	
An 8 year-old boy of Turkish ancestry, who was the offspring of a second-cousin union, 
was evaluated in liver clinic. He was born at full term without complications, and had no 
family history of liver or neurologic disease in his parents or 10 year-old sibling. At 8 
months of age he presented with vomiting presumed to be secondary to acute 
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gastroenteritis, and was found to have elevated transaminases. Liver and spleen were 
not enlarged. Over subsequent years, transaminase levels were intermittently elevated 
(aspartate aminotransferase 30-131 U/L, normal range 10-30 U/L); alanine 
aminotransferase 19-297 U/L, normal range 6-29 U/L), with normal gamma-glutamyl 
transpeptidase (GGT) levels and preserved liver synthetic function as indicated by 
normal albumin, bilirubin and INR levels. He also had hypolipidemia (total cholesterol 
less than 100mg/dL or low-density lipoprotein (LDL) less than 50mg/dL), with his total 
serum cholesterol ranging from 75-96 mg/dL and LDL-cholesterol 14-44 mg/dL; he also 
had vitamin D deficiency (serum level ranging from 12-17 ng/mL, normal range=20- 
50ng/mL), but normal levels of liposoluble vitamins A and E. Additionally, he had an 
elevated steatocrit (a semiquantitative measure of fat content in fecal samples), 
indicating steatorrhea and fat malabsorption. Serologies for viral hepatitis, TORCH 
(Toxoplasma gondii; Other: coxsackievirus, chickenpox, chlamydia, HIV, HTLV, syphilis; 
Rubella; CMV; HSV-2), and EBV, tests for autoimmunity (immunoglobulin G level; anti- 
smooth muscle, anti-nuclear, anti-double strained DNA, anti-liver kidney microsomal, 
anti-soluble liver pancreas, anti-cytosolic, anti-tissue transglutaminase and anti- 
thyroglobulin antibodies), and metabolic tests (alpha-1-antitrypsin, ceruloplasmin, urine 
copper levels, urine organic acid analysis, sweat chloride test), were all normal. 
Abdominal ultrasound with doppler study was unremarkable. 
	
	
	
The proband underwent a liver biopsy at 6 years of age; in contrast to a normal liver, the 
patient’s liver showed many thin fibrous septa, swollen hepatocytes, glycogenated 
nuclei and focal acinar transformation, consistent with hepatocellular injury and 
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regeneration (Figure 1, Supplementary Figure 1A). There was no obvious cholestasis, 
cholate stasis or steatosis. The fibrous septa and portal areas showed sparse 
lymphocytes without any interface activity and there was no lobular inflammatory activity 
or evident acidophil bodies. Trichrome stain showed thin fibrous septa and some 
nodularity (“incomplete septal cirrhosis”), with no features of well-established cirrhosis 
(Supplementary Figure 1B). 
	
The proband’s growth has been normal, with weight, height and head circumference 
ranging between 5th-90th, 50th-75th and 25th-50th percentile, respectively. Specifically, 
patient’s weight, height and head circumference were 2500 g (5th percentile), 49 cm 
(50th percentile) and 34 cm (25th percentile) at birth; and 33.8 Kg (90th percentile), 133 
cm (75th percentile) and 53 cm (50th percentile) at age 8 on his last clinic visit in June 
	
2016. 
	
	
	
	
The proband also had neurologic abnormalities. Developmental milestones included 
social smile at 3 months (mild delay), sitting at 6 months and walking at 14 months of 
age (within normal limits). He demonstrated mild delay in language development, 
producing several single words by 2.5 years and sentences by 5 years of age. At 6.5 
years of age, his parents and elementary school teachers noted mild intellectual 
disability. Neurological examination was remarkable for slurred speech, vertical gaze 
palsy, slight dysmetria, and mild gait ataxia. The ocular fundus exam was normal 
	
bilaterally. Wechsler Intelligence Scale for Children (WISC)-Revised test showed a total 
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score of 66 points (average range 90-110), supporting the diagnosis of mild intellectual 
disability. Brain magnetic resonance imaging (MRI) was reported as normal. 
	
	
	
Homozygous loss-of-function mutation in ACOX2 
The proband’s exome was sequenced to a mean depth of 60 independent reads per 
targeted base, with 96% of targeted bases having more than eight independent reads, 
providing high confidence calling of homozygous and heterozygous variants across the 
exome (Supplementary Table 1). Since the affected child is the offspring of second- 
cousin union (Figure 1D), we sought rare alleles (allele frequency ≤ 0.01 in databases) 
	
that were likely to result in loss of function of the encoded protein (i.e., premature 
termination, frameshift and splice site variants) that were homozygous in the proband. 
Consistent with consanguinity, this analysis identified five rare homozygous genotypes 
in the proband. Four of these resulted in missense variants that were predicted to be 
tolerated variants by MetaSVM and unlikely to be pathogenic in this patient 
(Supplementary Table 2). The other homozygous variant encoded premature 
termination at codon 69 (NM_003500, p. Y69*) in ACOX2, which encodes a branched- 
chain acyl-CoA oxidase, a peroxisomal enzyme expressed in the liver and kidney and 
believed to be involved in bile acid biosynthesis(8). This variant allele was absent 
among >100,000 alleles in the ExAC database, and >1500 alleles in people of Turkish 
ancestry, and was not found in any other database examined. Moreover, no 
homozygous loss-of-function genotypes in this gene were found among approximately 
61,000 exomes in ExAC or 894 people of Turkish ancestry. Sanger sequencing 
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confirmed the homozygous variant in the proband and showed that both parents and his 
	
brother were heterozygous for this variant (Figure 1E). 
	
	
	
	
ACOX2 is absent in proband’s liver 
	
The livers of normal control subjects and the proband were stained with antibodies 
specific for ACOX2. While normal liver showed intense granular staining in the 
pericentral (zone 3) hepatocytes (Figure 2A-C), along with faint hepatocellular 
cytoplasmic staining, the proband’s liver showed complete absence of staining, 
consistent with the mutation resulting in absence of this protein (Figure 2D-F). 
	
	
	
Elevated levels of bile acid intermediates 
	
The primary bile acids, cholic acid and chenodeoxycholic acid, are derived from 
cholesterol in the liver by the action of at least 14 different enzymes(9). The final steps 
of bile acid synthesis occur in peroxisomes; ACOX2, a peroxisomal branched-chain 
acyl-CoA oxidase, is believed to mediate the first step in the beta-oxidation of 27 carbon 
	
(C27) bile acid intermediates into 24 carbon (C24) bile acids(8, 10), resulting in the CoA 
	
esters of cholic and chenodeoxycholic acid (Figure 3). We consequently examined the 
	
proband’s plasma and urine for elevated levels of C27-bile acids upstream of ACOX2 
activity. Consistent with loss of ACOX2 function, the proband’s plasma and urine 
showed striking elevation of the C27 intermediate bile acids 3〈,7〈-dihydroxy-5®- 
cholestanoic acid (DHCA) and 3〈,7〈,12〈-trihydroxy-5®-cholestanoic acid (THCA), 
principally as the taurine conjugates (Table 1). For example, the proband’s plasma 
Tauro-THCA level was 7.94 µM, 25-fold higher than the upper limit of normal (0.31 µM), 
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and urinary Tauro-THCA was 66.19 µmol/mol creatinine; this metabolite is normally 
absent in urine. The proband shows low normal levels of cholic acid and conjugates, as 
seen in other bile acid biosynthesis disorders(11). The proband’s heterozygous parents 
showed no elevation of C27 intermediate bile acids. These findings indicate that 
homozygous loss of ACOX2 results in defective peroxisomal beta-oxidation of DHCA- 
CoA and THCA-CoA. 
	
	
	
ACOX2 has also been thought to be involved in the degradation of long branched fatty 
acids (phytanic and pristanic acids)(8). Interestingly, however, the proband’s branched- 
chain fatty acids (phytanic and pristanic acids) were both within the normal range (Table 
1). As expected, there was no elevation of very long chain fatty acids in the plasma, 
consistent with their metabolism by straight-chain acyl-CoA oxidase (ACOX1). 
	
	
	
DISCUSSION 
	
Our findings define a new inborn error of bile acid synthesis in a child with intermittent 
elevated transaminases, liver fibrosis, and mild neurological impairment, and implicate 
homozygous loss of ACOX2 in its pathogenesis. The evidence implicating ACOX2 is 
strong. The proband has the first reported homozygous loss of function mutation in 
ACOX2, no evidence of ACOX2 protein in his liver, and biochemical analysis shows the 
elevation of C27 bile acid intermediates predicted to result from loss of ACOX2 function, 
along with low or low-normal levels of downstream primary bile acids. His 
hypocholesterolemia, fat malabsorption and vitamin D deficiency are expected findings 
owing to decreased intestinal absorption of fat and lipids with reduced bile acid 
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secretion into the gut. Of note, the proband’s heterozygous 10-year old brother (total 
	
cholesterol, TC, 162 mg/dl, LDL cholesterol 85 mg/dl), mother (TC 159, LDL 78) and 
	
father (TC 204, LDL 97) all had normal lipids, providing no evidence of a phenotype in 
	
the heterozygous state. 
	
	
	
	
Additionally, intermediate bile acids are believed to be hepato- and neurotoxic(12, 13) 
providing likely explanations for the proband’s elevated transaminases, liver histology 
and neurologic defects. Indeed, mild to severe hepatocellular damage and/or neurologic 
impairment, including ataxia and intellectual disability, is seen in other defects in bile 
acid synthesis(9). Alternatively, deficiency of ACOX2 enzymatic activity and its 
	
downstream metabolites, and/or an independent function of ACOX2 could contribute to 
	
the proband’s neurological and cognitive impairment. No other variants were identified 
	
that were likely to explain aspects of the clinical features seen in the proband. The full 
spectrum of clinical features attributable to loss of ACOX2 will need to be determined by 
the study of additional patients with ACOX2 deficiency; this report should stimulate 
study of other children with unexplained elevation in transaminases and/or neurologic 
features. 
	
	
	
Other patients previously described with increases in C27 bile acid intermediates 
without general peroxisomal defects have proven distinct from ours. A patient with 
cirrhosis and liver failure at age four had recessive loss of ABCD3(14), which transports 
branched-chain acyl CoAs into peroxisomes; like our patient, this patient had normal 
levels of phytanic and pristanic acid. Other patients have been described with 
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sensorimotor neuropathy with recessive loss of alpha-methyl-acyl-CoA racemase 
(AMACR)(15), the enzymatic step in bile acid synthesis prior to ACOX2. These patients 
have elevated levels of phytanic and pristanic acid. 
	
	
	
While ACOX2 has also been proposed to be involved in the oxidation of long branched 
fatty acids(8, 10), normal levels of phytanic and pristanic acids were measured in the 
proband’s plasma. In humans, phytanic and pristanic acids are dietary in origin, 
predominantly from dairy products, beef and lamb(16). The proband is not vegetarian 
and ingests dairy products and beef regularly, providing no support for low dietary 
intake. These findings suggest that another pathway (e.g. omega-oxidation) can 
achieve full catabolism of these branched-chain fatty acids in children. The fact that 
phytanic and pristanic levels are elevated in patients without AMACR, which converts 
2R pristanoyl-CoA to the S enantiomer, suggests that this alternate pathway can only 
metabolize S enantiomers. We infer that as a consequence of ACOX2 deficiency, C27- 
intermediate bile acids accumulate in peroxisomes as CoA esters and are readily 
converted into taurine conjugates (by bile acyl-CoA amino acid acyltransferase, BAAT), 
and much smaller amounts are converted to glycine conjugates. This is consistent with 
the observation that taurine conjugates predominate in peroxisome biogenesis 
disorders(17). 
	
	
	
Importantly, the clinical consequences of defects in bile acid synthesis can be mitigated 
using primary bile acid therapy. Oral bile acid replacement with cholic acid reduces 
endogenous bile acid synthesis, thereby decreasing the accumulation of toxic bile acid 
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intermediates and correcting fat malabsorption(18, 19). This therapy has also proved 
effective in normalizing transaminases and improving neurologic findings(20). Since the 
proband shows low normal levels of cholic acid and conjugates, cholic acid therapy has 
the potential for clinical impact; a trial with close monitoring of liver function tests and 
bile acid intermediates levels is planned. 
	
	
	
To date, most peroxisomal disorders have been diagnosed via the identification of 
probands with severe phenotypes with marked biochemical abnormalities, such as 
increased levels of substrates normally handled by peroxisomes (VLCFAs, pristanic 
acid, phytanic acid, DHCA, THCA) and decreased levels of end products of peroxisomal 
metabolism (cholic and chenodeoxycholic acid), followed by investigation leading to 
identification of the genetic defect. It is noteworthy that our patient presented with a 
relatively non-specific clinical presentation, and that a primary defect in bile acid 
biosynthesis was not considered prior to identification of the ACOX2 mutation. 
Particularly because of the potential for mitigation of the clinical consequences of 
ACOX2 deficiency, this diagnosis should be considered in children with unexplained 
transaminase elevations and neurologic abnormalities, and raise the question of 
whether ACOX2 mutation might also contribute to cases of cryptogenic cirrhosis later in 
life. 
	
	
	
MATERIALS AND METHODS 
	
DNA isolation, exome capture and sequencing. Genomic DNA of the proband, his 
unaffected parents, and brother was isolated from peripheral blood leukocytes 
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using standard procedures. Exome sequencing of the proband was performed 
using the Roche/Nimblegen SeqCap EZ Human Exome Library v2, with 74 base 
paired-end sequencing on the Illumina HiSeq platform as previously 
described(21). 
	
	
	
Exome Analysis. Exome sequence data was aligned to the reference human genome 
(build 19) and variants were called using GATK; the impact of missense variants was 
predicted using MetaSVM(22). Allele frequencies of identified variants were determined 
in the NHLBI Exome Variant Server (4,300 European and 2,203 African-American 
subjects; last accessed March 2015), 1000 Genomes (1,094 subjects of various 
ethnicities), the Exome Aggregation Consortium (ExAC; 61,000 subjects of various 
ethnicities; January 2015 release), and a Yale database of 894 Turkish exomes, 
predominantly of consanguineous union. 
	
	
	
Sanger sequencing of genomic DNA. Sanger sequencing of the identified ACOX2 
mutation (p.Y69*) was performed by PCR amplification of genomic DNA of the 
proband, his parents and his sibling using forward primer: 5’- 
TCTTCTAACCAACCCAGGCG-3’, and reverse primer: 5’- 
CAGAAACCTCACCCAGGTCC-3’. Nomenclature of the ACOX2 variant is based 
on NCBI reference sequence NM_003500. 
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ACOX2 liver immunohistochemistry. Anti-ACOX2 antibody from Sigma-Aldrich 
(HPA038280) at 1:200 dilution was used to perform immunohistochemistry in normal 
and ACOX2-mutant liver sections using standard techniques. 
	
	
	
Mass spectrometry. Analysis of cholanoic acids (normal bile acids) and their taurine and 
glycine conjugates was performed by targeted UPLC-MS/MS essentially as described 
by(23). The following modifications were used to include analysis of cholestanoic acids 
(C27 bile acids): THCA (3〈,7〈,12〈-trihydroxy-5®-cholestanoic acid) and [27,27,27-D3]- 
THCA were purchased from Dr. Herman Ten Brink, VU Medical Centre, Amsterdam, 
Netherlands. UPLC retention times and mass spectrometry transitions for the C27 bile 
acids are shown in Supplementary Table 3. Quantitation of glycine and taurine 
conjugates was achieved by measuring the ratio of the peak area produced by the C27 
bile acid in the patient sample to the corresponding deuterated C24 bile acid standard 
e.g. tauro-THCA/D5-taurocholic acid. Some compounds were identified by comparison 
to samples from previous patients diagnosed with peroxisomal disorders. 
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FIGURE LEGENDS 
	
Figure 1. Liver histology and ACOX2 mutation in a subject with a novel bile acid 
synthesis disorder. (A) Liver parenchyma of proband shows many thin fibrous septa 
(black arrows) and some nodularity (“incomplete septal cirrhosis”). Features of well- 
established cirrhosis are not seen. (B) Details of the lobular parenchyma show swollen 
hepatocytes (asterisks), glycogenated nuclei (black arrows) and very thin incomplete 
fibrous-septa (blue arrow). (C) Liver parenchyma from age and gender matched patient 
	
showing normal-appearing portal tracts and a central venule (asterisk). The lobular 
	
architecture is preserved with no fibrosis. (D) The affected proband and unaffected 
	
subjects are shown with black and white symbols, respectively. Consanguineous union 
is shown with a double line. ACOX2 alleles are denoted WT (wild-type) or Mut (p. Y69*). 
(E) Sanger sequencing chromatograms of the proband, his unaffected parents and 
	
brother. The ACOX2 p.Y69* mutation is homozygous in the proband and heterozygous 
in the unaffected parents and sibling. Scale bars, 50µm. 
	
	
	
Figure 2. Absence of ACOX2 in proband’s liver. (A, B, C) Immunohistochemistry for 
ACOX2 in normal liver shows intense granular staining in the pericentral (zone 3) 
hepatocytes. The staining in remaining hepatocytes, including periportal hepatocytes 
(zone 1) is faint. (D, E, F) Immunohistochemistry for ACOX2 in the proband’s liver 
biopsy, showing complete absence of staining. Scale bars, 50µm. 
	
	
	
Figure 3. Schematic representation of β-oxidation of trihydroxycholestanoyl-CoA by 
	
ACOX2. ‘CA’ denote cholic acid. 
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Figure 3 
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Tauro-DHCA,  0.32    0-  
Tauro-THCA,  7.94    0 -  
Glyco-DHCA,  0.06    0 -  
Glyco-THCA,  0.24    0 -  
DHCA,  0.262    0 -  
THCA,  0.10    0 -  
ile  
Glycodihydroxycholanoates,     0.22 -  
Glycocholate,     0.05 -  
Taurodihydroxycholanoates,     0.03 -  
Taurocholate,     0.001 -  
Dihydroxycholanoates,  0.03    0.09 -  
Cholate,     0.003 -  
 	 	 	 	
C26:0,     ≤  
C24:0,     ≤  
C22:0,     ≤  
    ≤  
    ≤  
ranched-chain fatty  
Phytanic acid,     ≤  
Pristanic acid,     ≤  
	
0.24     
66.19     
371.1    0 -  
14.11    0 -  
53.93    0 -  
	
    
	
Table 1. Biochemical data from proband’s plasma and urine. 				
	
Parameter  Proband Mother Father Reference   Values   
ACOX2 genotype (p.Y69*) 
Plasma 
Bile acid intermediates 
	
	
	
	
	
	
	
	
B 
	
	
	
	
	
	
	
	
V 
	
	
	
	
	
	
B 
	
	
Urine 
Bile acid intermediates 
Tauro-DHCA (µmol/mol creat) 
Tauro-THCA (µmol/mol creat) 
Tauro-tetraOH-cholestanoic 
acids (µmol/mol creat) 
Glyco-THCA (µmol/mol creat) 
Glyco-tetraOH-cholestanoic 
acids (µmol/mol creat) 
  THCA (µmol/mol creat)  4.62 (↑)  0  0  0 - 0.13   
	
VLCFA = very long chain fatty acids; DHCA = 3〈,7〈-dihydroxy-5®-cholestanoic acid; THCA = 
3〈,7〈,12〈-trihydroxy-5®-cholestanoic acid; n.a. = not assessed; (↑) = above the reference values; (↓) = 
below the reference values. 
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SUPPLEMENTARY INFORMATION 
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Supplementary Figure 1. Additional histological findings in the proband’s liver. (A) Hepatocytes 
are pale and swollen with focal acinar transformation (black arrows). Scale bar, 50µm. (B) Low 
magnification of liver biopsy showing thin fibrous septa (black arrows) and some nodularity on 
Trichrome stain. Scale bar, 200µm. 
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Supplementary Table 1. Sequencing coverage and quality metrics for the proband’s exome. 
	
	
	
	
Mean independent reads per targeted base 
	
59.8 
	
% of bases mapping to genome 
	
91.14 
	
% of targeted bases with ≥ 8 independent reads 
	
95.9 
	
Mean error rate (%) 
	
0.44 
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Supplementary Table 2. Rare homozygous protein-altering variants detected in the proband. 
	
	
	
	
Gene 
	
Chr: position 
	
AA 
	
MetaSVM 
	
NHLBI 
	
1000G 
	
Turkish DB 
	
ExAC 
	
ExAC 
Symbol (hg19) change score 	 	 (894 subjects) (overall) (highest   (Prediction)  subfrequency)   
	
	
ACOX2 3:58520203 Y69* Truncating 0 0 0 0 0 
	
	
	
CHDH 3:53851817 A591V -1.051 (T) 0 0 0 0 0 
	
	
	
LRRIQ1 12:85531684 I1422M -0.927 (T) 0.007414 0.01 0.0006 0.00861  0.02184 
(South Asian) 
	
	
OSBPL6 2:179255872 R817W -0.412 (T) 0 0 0 0 0 
	
	
RASEF 9:85620405 R347W -0.118 (T) 0 0 0 4.94E-05  0.0002312 
(East Asian) 
	
None of the above genes are OMIM-related genes; Chr, chromosome; AA, amino acid; NHLBI, National Heart, 
Lung, and Blood Institute Exome Sequencing Project database; 1000G, 1000 Genome database; DB, database; 
ExAC, Exome Aggregation Consortium database; MetaSVM scores missense variants on a scale from -2 to 3, with 
scores < 0 predicted to be tolerated (T) and scores > 0 predicted to be damaging (D). 
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Supplementary Table 3. Retention times, cone voltage, collision energy, precursor and product 
	
ions used in identification of bile acids detected in patients with peroxisomal disorders. 
	
	
	
Bile acid1 
Conjugation Retention Cone Collision Precursor Product ion 
	
Dihydroxycholestanoic, DHCA 
[Abbreviation] time (min) voltage (V) energy (V) ion (m/z) (m/z) 
(3〈,7〈-diOH-5®-C27) 
Trihydroxycholestanoic, THCA 
(3〈,7〈,12〈-triOH-5®-C27) 
Tetrahydroxycholestanoics, 
hydroxy-THCA (3〈,7〈,12〈,⎩- 
tetraOH-5®-C27) 
Dihydroxycholestanoic, DHCA 
(3〈,7〈-diOH-5®-C27) 
Trihydroxycholestanoic, THCA 
(3〈,7〈,12〈-triOH-5®-C27) 
Tetrahydroxycholestanoics, 
hydroxy-THCA (3〈,7〈,12〈,⎩- 
tetraOH-5®-C27) 
Dihydroxycholestanoic, DHCA 
(3〈,7〈−diOH-5®-C27) 
Trihydroxycholestanoic, THCA 
(3〈,7〈,12〈-triOH-5®-C27) 
Tau [Tauro-DHCA] 1.85 116 59 540.0 80.0 
	
Tau [Tauro-THCA] 1.91 116 59 556.3 80.0 
	
Tau [Tauro-tetraOH- 
cholestanoics] 
1.5 - 1.8 116 59 572.0 80.0 
	
Gly [Glyco-DHCA] 1.85 88 31 490.0 74.0 
	
Gly [Glyco-THCA] 1.78 88 31 506.0 74.0 
	
Gly [Glyco-tetraOH- 
cholestanoics] 
1.56 88 31 522.0 74.0 
	
None [DHCA] 1.94 86 10 433.0 433.0 
	
None [THCA] 1.86 86 10 449.3 449.3 
D3-THCA None [D3-THCA] 1.86 86 10 452.3 452.3 
15b-C27, 5b-cholestan-26-oic acid; 2Tau, taurine; Gly, glycine. 
